Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
VCEL

VCEL - Vericel Corp Stock Price, Fair Value and News

$36.22-0.36 (-0.98%)
Market Closed

35/100

VCEL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

35/100

VCEL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$30.28

Target 3M

$35.39

Target 6M

$33.08

VCEL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VCEL Price Action

Last 7 days

-4.0%

Last 30 days

-3.6%

Last 90 days

4.9%

Trailing 12 Months

-39.7%

VCEL RSI Chart

VCEL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VCEL Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

140.02

Price/Sales (Trailing)

7.08

EV/EBITDA

47.39

Price/Free Cashflow

89.9

VCEL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$30.28

Target 3M

$35.39

Target 6M

$33.08

VCEL Fundamentals

VCEL Revenue

Revenue (TTM)

258.7M

Rev. Growth (Yr)

16.58%

Rev. Growth (Qtr)

6.74%

VCEL Earnings

Earnings (TTM)

13.1M

Earnings Growth (Yr)

663.15%

Earnings Growth (Qtr)

1.0K%

VCEL Profitability

EBT Margin

11.29%

Return on Equity

4.06%

Return on Assets

2.89%

Free Cashflow Yield

1.11%

VCEL Investor Care

Shares Dilution (1Y)

2.46%

Diluted EPS (TTM)

0.26

VCEL Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025238.5M249.1M258.7M0
2024207.8M214.5M226.8M237.2M
2023169.3M178.2M185.2M197.5M
2022157.7M155.2M159.3M164.4M
2021132.1M151.6M153.8M156.2M
2020122.7M116.6M118.3M124.2M
201994.6M101.8M109.8M117.8M
201872.6M74.6M82.9M90.9M
201756.5M60.6M63.9M63.9M
201654.4M53.7M53.3M61.2M
201539.6M48.8M50.5M51.2M
2014017.3M23.0M28.8M
201327.0K30.0K5.8M11.5M
201211.0K11.0K2.0K21.0K
201153.5K41.7K29.8K18.0K
20100077.2K65.3K
Get all data in R, Python etc through our Historical Stock Data APIs

About Vericel Corp

VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEhttps://vcel.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES305

Vericel Corp Frequently Asked Questions

VCEL is the stock ticker symbol of Vericel Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Vericel Corp is 1.83 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check VCEL's fair value in chart for subscribers.

The fair value guage provides a quick view whether VCEL is over valued or under valued. Whether Vericel Corp is cheap or expensive depends on the assumptions which impact Vericel Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VCEL.

As of Wed Jan 28 2026, VCEL's PE ratio (Price to Earnings) is 140.02 and Price to Sales (PS) ratio is 7.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VCEL PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Vericel Corp has provided 0.329 (multiply by 100 for percentage) rate of return.